GlassScriptPhysician profile
Mary Chandler
NPI 1780082206
$3,654.88
in general payments reported to CMS, 2019-2025
21 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $371 · 2023: $499 · 2024: $756 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,713 · Education: $32.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,712.83 |
| Education | $32.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $657.65 | 2021-2025 | Caplyta |
| Abbvie INC. | $492.89 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $460.33 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $400.00 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $387.07 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $275.76 | 2023-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $200.34 | 2022-2025 | Fanapt |
| Lundbeck LLC | $195.17 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $154.33 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $136.30 | 2021-2024 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $83.72 | 2022-2025 | Auvelity |
| Lilly USA, LLC | $50.29 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $30.62 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.02 | 2024 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $20.25 | 2025 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $16.52 | 2024 | Senza |
| Phathom Pharmaceuticals, INC. | $15.63 | 2024 | Voquezna |
| Alcon Vision LLC | $15.23 | 2022 | |
| Metacel Pharmaceuticals LLC | $13.36 | 2025 | Ozobax |
| Avanir Pharmaceuticals, INC. | $11.80 | 2021 | |
| Sunovion Pharmaceuticals INC. | $9.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.